Influenza A virus vaccine H5N1 - Kitasato Daiichi Sankyo Vaccine

Drug Profile

Influenza A virus vaccine H5N1 - Kitasato Daiichi Sankyo Vaccine

Alternative Names: Cell culture-based pandemic influenza vaccine - Kitasato Daiichi Sankyo Vaccine; Cell-culture H5N1 flu vaccine - Kitasato Daiichi Sankyo Vaccine; H1N1 vaccine - Kitasato Daiichi Sankyo Vaccine; H5N1 vaccine - Kitasato Daiichi Sankyo Vaccine; KIB PCI; Pandemic influenza vaccine - Kitasato Daiichi Sankyo Vaccine; VN 101

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kitasato Daiichi Sankyo Vaccine
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H5N1 subtype

Most Recent Events

  • 30 Nov 2017 Kitasato Daiichi Sankyo Vaccine has been acquired by Daiichi Sankyo Company
  • 01 Jun 2016 No development reported - Phase-III for Influenza-A virus H5N1 subtype (Prevention, In adults) in Japan (IM)
  • 01 Mar 2016 MHLW approves the optimal dose of influenza A H5N1 virus vaccine for use in paediatric patients in Japan (Daiichi Sankyo pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top